NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Geert R. D'Haens  ¹     Marla C. Dubinsky  ²     Miguel Regueiro  ³     Genoile O. Santana  ⁴     Joana Torres  ⁵     nicole kulisek  ⁶     Sean Gardiner  ⁷     Rajiv Mundayat  ⁷     Jerome Paulissen  ⁷     Nervin Lawendy  ⁷     Chinyu Su  ⁷     Irene Modesto  ⁷     William Sandborn  ^8    
1 Amsterdam University Medical Centres, Amsterdam, Netherlands
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Cleveland Clinic, Cleveland, United States
⁴ University of the State of Bahia, Salvador, Brazil
⁵ Hospital Beatriz Ângelo, Loures and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
⁶ Pfizer Inc, Collegeville, United States
⁷ Pfizer Inc, New York, United States
⁸ University of California San Diego, La Jolla, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)